PuSH - Publikationsserver des Helmholtz Zentrums München

Kennedy, P.T.* ; Allweiss, L.* ; Bertoletti, A.* ; Cornberg, M.* ; Gehring, A.J.* ; Guidotti, L.G.* ; Kerth, H.A. ; Lemoine, M.* ; Levrero, M.* ; Lim, S.G.* ; Tavis, J.E.* ; Testoni, B.* ; Tu, T.*

Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.

Lancet Gastroenterol. Hepatol., DOI: 10.1016/S2468-1253(25)00053-6 (2025)
DOI PMC
Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curative, and patients remain at risk of cirrhosis and hepatocellular carcinoma. Treatment guidelines have generally restricted antiviral therapy to individuals with high HBV DNA and elevated ALT or hepatic fibrosis, often requiring longitudinal testing that can be scarcely available in resource-limited settings. Consequently, fewer than 3% of people living with HBV infection are receiving antiviral therapy. Guidelines from China and WHO recently broadened access criteria to antiviral therapy, but there are people who fall outside these guidelines who could still benefit from treatment initiation. The pathological processes induced by HBV infection are still active in these patients. We present the benefits and risks of expanding treatment eligibility. We believe that the benefits of reduced hepatic damage and carcinogenic stimuli greatly outweigh the risks.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
ISSN (print) / ISBN 2468-1253
e-ISSN 2468-1253
Zeitschrift The lancet : Gastroenterology & Hepatology
Verlag Elsevier
Verlagsort London
Nichtpatentliteratur Publikationen
Institut(e) Institute of Virology (VIRO)